The pathway to commercialization for nanomedicine.
Nanomedicine is a global opportunity that will change the face of medicine and drug delivery in the next 20 years. To date, US firms have focused primarily on the science and less on the commercial application of nanomedicine. As a result, there remain significant obstacles in bringing a nanomedicine product to market. Overcoming those obstacles will require a multidisciplinary approach to commercialization. This article will look at the emerging nanomedicine market, the current view from the investment community, and some of the obstacles facing the commercialization of nanomedicine science.
Flynn
Ted
T
Potomac Investment Capital, LLC, Sterling, Virginia, USA.
Wei
Chiming
C
D003132:Commerce / Q000191:economics*; D018795:Device Approval; D007221:Industry / Q000191:economics*; D007449:Investments / Q000191:economics*; D050997:Nanomedicine / Q000191:economics*; D018581:Technology Transfer; D014481:United States; D014486:United States Food and Drug Administration